Bristol-Myers' senior VP of global development retires

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Bristol's senior VP of global development retires

Bristol-Myers Squibb's ($BMY) Brian Daniels, senior vice president of global development and medical affairs, will leave the company in July this year, having served almost 15 years with the company. Daniels led the development of the revolutionary melanoma drug Yervoy, according to the company, as well as the next-generation clot-buster Eliquis. Release

Bristol-Myers Squibb
Brian Daniels is retiring.

Biotech

Elekta has appointed Åsa Hedin as executive vice president of corporate strategy and Maurits Wolleswinkel as executive vice president of neuroscience. Release

Neuralstem ($CUR) has appointed Sandford Drexel Smith, the former executive vice president of Genzyme, to its board of directors. Release

John Harland has joined Vaxart as chief financial officer, replacing David Madden, who served as acting CFO. Release

Scil Proteins has appointed Dr. Henning Afflerbach as CEO and Dr. Ulrich Haupts as managing director in addition to his current role as chief scientific officer. Release

Tokai Pharmaceutical has appointed Khalid Mamlouk as vice president and head of medical affairs. Release

Global Genomics Group has appointed Harry "Chip" Davis Jr. as chief drug development officer. Release

GW Pharmaceuticals ($GWPH) has appointed Dr. Kenneth Sommerville to the newly created position of vice president of clinical science. Release

Dr. Paul Billings joined Omicia as its chief medical officer. Release

Memorial Sloan-Kettering's Dr. Howard Scher will continue to lead its Phase I trial for AV Therapeutics' prostate cancer drug. Release

ProGDerm brought on J. Michael Delmage as its CEO. Release

Eleven Biotherapeutics ($EBIO) appointed Dr. Gary Sternberg as its executive vice president of corporate and business development. Release

Dr. Gaurav Aggarwal joined Ocera Therapeutics as the company's chief business officer. Release

Pharma

> Pharmagen has added Frederick Mundt as senior vice president of sales. Release

Former Forest Laboratories ($FRX) general counsel Herschel Weinstein joined Lowenstein Sandler as senior counsel and vice chair. Release

Rich Pharmaceuticals appointed Chieanchuang Kalayanamitr to its medical advisory board. Release

Diagnostics

DNA Electronics appointed Dr. Steve Allen as chief operating officer. Release

Drug Delivery

Unilife ($UNIS) appointed John Ryan as senior vice president, general counsel and secretary. Release

CRO

Cobra Biologics has appointed Daniel Smith as its chief scientific officer. Release

Vaccines

Novavax ($NVAX) appointed Sven Andreasson as the company's senior vice president of corporate development. Release